- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Fundamentals of CVD Risk Assessment: Guideline Topline for Primary Care
Assessment of CVD risk is the foundation of primary prevention and integral to primary care. Brush up on the fundamental tools of risk estimation from the ACC/AHA guidelines.
CLINICAL FOCUS: PREVENTIVE CARDIOLOGY
Assessment of atherosclerotic cardiovascular disease (ASCVD) risk, the foundation of primary prevention, is a critical guide for decision-making about potential interventions, including pharmacotherapy.
The American College of Cardiology (ACC)/American Heart Association (AHA) 2019 clinical practice guidelines emphasize the essential roles of clinician-patient discussions and a patient-centered approach to all treatment decisions whether the topic is lifestyle change or initiating medication.
In this Guideline Topline slide show, get a concise summary of the recommended tools for evaluating patient CVD risk, refining the risk, and for placing the patient at the center of therapeutic choice.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
